Breaking News Instant updates and real-time market news.

GPRO

GoPro

$14.30

-0.72 (-4.79%)

, AMZN

Amazon.com

$834.09

3.09 (0.37%)

09:15
10/13/16
10/13
09:15
10/13/16
09:15

On The Fly: Pre-market Movers

HIGHER: Ocular Therapeutix (OCUL), up 24% after the company announced a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (REGN) to collaborate on the development of a sustained release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases... Ulta Beauty (ULTA), up 3% after the company raised its forecast for Q3 earnings and its full-year profit growth view... Esperion Therapeutics (ESPR), up 5.5% after the company announced that top-line results from its Phase 2 study of bempedoic acid added to atorvastatin 80 mg demonstrated the eight-week study met its primary endpoint of greater LDL-C lowering from baseline. LOWER: GoPro (GPRO), down 4% after Piper Jaffray analyst Erinn Murphy said she has uncovered that the action camera maker is currently not selling via Amazon (AMZN) in the U.S... Fluidigm (FLDM), down 20% after the company announced preliminary Q3 revenue below analysts' estimates and suspended its full year 2016 guidance... MercadoLibre (MELI), down 6.7% after eBay (EBAY) said it will sell a majority of its stake in the company... Insys Therapeutics (INSY), down 4% after announcing preliminary estimated Q3 revenues from Subsys sublingual spray that were below estimates... Deckers Brands (DECK), down 5% after the stock was downgraded to Negative from Neutral at Susquehanna... Hortonworks (HDP), down 3.5% after the stock was downgraded to Sell from Buy at Goldman Sachs. DOWN AFTER EARNINGS: Marriott Vacations (VAC), down 9%.

GPRO

GoPro

$14.30

-0.72 (-4.79%)

AMZN

Amazon.com

$834.09

3.09 (0.37%)

DECK

Deckers Brands

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

MELI

MercadoLibre

$183.21

-1.26 (-0.68%)

EBAY

eBay

$31.50

0.04 (0.13%)

FLDM

Fluidigm

$7.05

-0.29 (-3.95%)

INSY

Insys Therapeutics

$11.87

-0.34 (-2.78%)

ULTA

Ulta Beauty

$238.97

2.31 (0.98%)

VAC

Marriott Vacations

HDP

Hortonworks

$7.46

-1.24 (-14.25%)

ESPR

Esperion

$12.32

-0.58 (-4.50%)

  • 13

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 02

    Nov

  • 03

    Nov

  • 04

    Nov

  • 06

    Nov

  • 14

    Nov

  • 29

    Nov

  • 07

    Dec

  • 12

    Dec

  • 29

    Mar

  • 14

    Oct

GPRO GoPro
$14.30

-0.72 (-4.79%)

09/20/16
09/20/16
NO CHANGE

Stifel still skeptical on new GoPro product line
Stifel analyst Jim Duffy remains skeptical about the ability of GoPro's new Hero5 products to restore enthusiasm in the company's offerings. The analyst says that the company's failure to incorporate "follow me" mode into its new Karma drone and the drone's high price tag are negative. The analyst thinks that Street forecasts of 20% revenue compound annual growth from 2016-2018 "appear aggressive." He keeps a Hold rating on the shares.
10/13/16
PIPR
10/13/16
NO CHANGE
Target $9
PIPR
Underweight
GoPro currently not shipping to Amazon, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says she uncovered that GoPro (GPRO) is not currently selling to Amazon (AMZN), at least domestically, in a change that occurred over the last three weeks. In a follow-up research note after speaking to management, Murphy clarified that the pause in shipping to Amazon is planned to be temporary. GoPro plans to resume shipping to Amazon at the end of October, Murphy adds. The action camera maker has been shipping to Best Buy (BBY), other partners and its own GoPro.com channel in the meantime, she points out. Nonetheless, the analyst believes the disruption at Amazon was not contemplated in guidance. Murphy is "incrementally concerned" on GoPro's ability to reach its second half of 2016 guidance. The analyst reiterates an Underweight rating on the shares with a $9 price target. The stock closed yesterday down 72c to $14.30.
09/28/16
OPCO
09/28/16
NO CHANGE
OPCO
DJI Mavic Pro not a response to GoPro Karma, says Oppenheimer
After drone market leader DJI unveiled its Mavic Pro, Oppenheimer analyst Andrew Uerkwitz notes that he does not see it as a response to GoPro's Karma, arguing that they have two very different value propositions. Mavic is a high-performance, versatile consumer drone that pushes boundaries of the category to new heights, while Karma is a well-rounded and versatile flying camera system, he contended. Nonetheless, Uerkwitz believes GoPro's brand and customer loyalty will be tested given an acceleration in innovation and several compelling drones introduced this year across the market.
09/28/16
BOFA
09/28/16
NO CHANGE
BOFA
New drone competitor won't knock down GoPro Karma, says BofA/Merrill
After DJI announced its Mavic drone, BofA/Merrill analyst Jason Mitchell says that the product will appeal more to drone enthusiasts, while GoPro's Karma drone will be more popular with casual consumers and those focused on film. The analyst sees "little risk" to his Q4 estimates for GoPro as a result of Mavic's launch ,since he did not expect GoPro to obtain much revenue from Karma in Q4. Although the analyst believes that Mavic increases GoPro's risk in fiscal 2017, he continues to believe that Karma will be able to obtain a 4%-5% share of the drone market in fiscal 2017. Mitchell keeps a $19 price target and Buy rating on GoPro.
AMZN Amazon.com
$834.09

3.09 (0.37%)

10/10/16
DBAB
10/10/16
INITIATION
Target $90
DBAB
Sell
Deutsche sees Netflix takeover as unlikely, starts shares at Sell
Deutsche Bank analyst Bryan Kraft initiated shares of Netflix (NFLX) with a Sell rating and $90 price target. The stock closed Friday down 25c to $104.82. The risk/reward is unattractive as consensus expectations reflect an "optimistic case," Kraft tells investors in a research note. Market expectations appear too high through 2020, the analyst contends. He also expresses skepticism that Netflix will be acquired. The business is "too fully formed" and valued to be acquired by Disney (DIS) and Apple (AAPL), Kraft writes. He also sees Amazon.com (AMZN) as a competitive risk to Netflix.
10/12/16
MSCO
10/12/16
NO CHANGE
Target $110
MSCO
Morgan Stanley sees 'un-grandfathering' peaking for Netflix in Q3
Morgan Stanley analyst Benjamin Swinburne believes the market expects Netflix (NFLX) to report Q3 domestic net subscriber additions that fall short of the company's 300K forecast. However, he thinks the impact of "un-grandfathering" will peak in Q3 and that the percentage of U.S. members seeing price increases will begin to fade in Q4. While acknowledging that Amazon (AMZN) continues to grow as a competitor for content and time spent, Swinburne notes that local and regional players in many markets continue to struggle. The analyst keeps an Overweight rating and $110 price target on Netflix shares.
10/12/16
CANT
10/12/16
NO CHANGE
Target $1000
CANT
Buy
Amazon.com price target raised to $1,000 from $835 at Cantor
Cantor Fitzgerald analyst Youssef Squali raised his price target for Amazon.com to $1,000 from $835 citing continued strength in core retail and sustained momentum in Web Services. The stock closed yesterday down $10.71 to $831.00. We're reaching a tipping point in e-commerce, with revenue growth in the U.S. accelerating year-over-year in the first nine months of 2016, Squali tells investors in a research note. This trend is "playing into the hands of market leader Amazon," the analyst contends. He points out that Prime's user base is growing and that Amazon's share of retail searches online is growing. The analyst expects Amazon Web Services' "strong economics" to continue to fund growth initiatives at Amazon. Squali sees the stock as continuing to "grind higher." He keeps a Buy rating on the name.
DECK Deckers Brands

10/13/16
SUSQ
10/13/16
DOWNGRADE
Target $49
SUSQ
Negative
Deckers Brands downgraded to Negative at Susquehanna
As reported previously, Susquehanna analyst Sam Poser downgraded Deckers Brands to Negative from Neutral as he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. The analyst also reduced his estimates and believes gross margin improvement will be below expectations. Poser lowered his price target to $49 from $59 on Deckers Brands shares.
08/15/16
08/15/16
UPGRADE

Outperform
Deckers Brands upgraded to Outperform at Telsey Advisory
As previously reported, Telsey Advisory upgraded Deckers to Outperform from Market Perform and raised its price target to $78 from $68. Analyst Kelly Chen said Deck has become more than just a winter story, although she expects weather will not be as unfavorable as it was last year, as new management is implementing real and meaningful changes that can improve sales and profitability, and drive growth over the long term. Chen highlights new and compelling product innovation, a more advanced and disciplined approach to segmenting the product and the distribution, and taking a hard line on driving efficiencies across the organization by reducing unproductive SKUs, improving lead times and closing stores that are not meeting the company's targets.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Deckers Brands initiated with a Neutral at Guggenheim
OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
MELI MercadoLibre
$183.21

-1.26 (-0.68%)

10/13/16
BARD
10/13/16
NO CHANGE
Target $35
BARD
Outperform
eBay sale of MercadoLibre stake adds financial flexibility, says Baird
Baird analyst Colin Sebastian said eBay's (EBAY) sale of a majority of its investment stake in MercadoLibre (MELI) will provide eBay with both financial and strategic flexibility. The analyst believes the capital will allow eBay to increase share buybacks, make strategic acquisitions, or expand more aggressively in Latin America under a new strategic agreement with MercadoLibre. Sebastian maintained his Outperform rating and $35 price target on eBay shares.
09/02/16
09/02/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MercadoLibre (MELI) upgraded to Overweight from Neutral at JPMorgan by analyst Andre Baggio, who said the Brazilian marketplace is thriving, and MercadoLibre is gaining market share. 2. Teva (TEVA) upgraded to Outperform from Perform at Oppenheimer by analyst Rohit Vanjani, who points out that the validity of Teva's Copaxone patents now lies with the District Court decision after the inter partes reviews by the USPTO. Vanjani believes the court ruling, which will likely come in early 2017, is the more important of the two, with a higher hurdle to invalidate the patents. 3. Pioneer Energy (PES) upgraded to Buy from Hold at Jefferies by analyst Brad Handler, who argues that the 24% pullback in shares since the early July peak provides an attractive valuation. The analyst believes Pioneer's covenant risk can be managed and raised his price target for the shares to $6 from $5. 4. Amec Foster Wheeler (AMFW) upgraded to Buy from Neutral at BofA/Merrill. 5. Mitsubishi UFJ (MTU) upgraded to Outperform from Neutral at Daiwa. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/02/16
JPMS
09/02/16
UPGRADE
Target $200
JPMS
Overweight
MercadoLibre upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Andre Baggio upgraded MercadoLibre to Overweight and raised his price target for the shares to $200 from $133. The Latin America online commerce platform closed yesterday up $1.68 to $173.68. The Brazilian marketplace is thriving, and MercadoLibre is gaining market share, Baggio tells investors in a research note. He expects the share price to be driven by earnings growth, despite the "rich valuation."
08/30/16
PIPR
08/30/16
NO CHANGE
Target $185
PIPR
Overweight
MercadoLibre listings growth continues, says Piper Jaffray
Piper Jaffray analyst Gene Munster says his firm's proprietary web analytics indicates MercadoLibre's listings growth continues at an "impressive rate." For July, the analyst thinks the company's unit growth was 85%. MercadoLibre's platform is "gaining steam with suppliers due to improvements in the site," Munster tells investors in a research note. He reiterates an Overweight rating on the shares with a $185 price target.
EBAY eBay
$31.50

0.04 (0.13%)

10/10/16
RHCO
10/10/16
NO CHANGE
RHCO
eBay outlook has improved, says SunTrust
SunTrust analyst Robert Peck says he's more confident about eBay's turnaround following its beat and raise results. However, the analyst warns that the company's turnaround still has a long way to go, while its competition is increasing. Peck thinks that the stock could "re-rate" as the company's outlook becomes more certain, but he keeps a Hold rating on the shares.
10/13/16
WEDB
10/13/16
INITIATION
WEDB
Neutral
eBay coverage assumed with a Neutral at Wedbush
Wedbush analyst Aaron Turner says that eBay's e-commerce initiatives should help slow its market share erosion. However, the analyst prefers to keep a Neutral rating on the shares until the company shows that its "recent growth is sustainable and/or accelerating." Target to $34 from $29.
10/03/16
BARD
10/03/16
NO CHANGE
BARD
Baird says impact on eBay from Facebook's Marketplace likely limited for now
Baird analyst Colin Sebastian said Facebook's (FB) launch of its long-anticipated peer-to-peer commerce platform, "Marketplace," came "much later" than he anticipated, but he still thinks Facebook is well positioned to compete in consumer shopping. Facebook's latest e-commerce effort will create headlines around competitive pressure, but Sebastian thinks Amazon (AMZN) and eBay (EBAY) will be "minimally impacted" in the near term given their scale, brand awareness, and much more advanced e-commerce capabilities. eBay may be most exposed, but the analyst also notes that 80% of its listings are new products, which may have limited overlap with Facebook listings.
FLDM Fluidigm
$7.05

-0.29 (-3.95%)

03/18/16
MZHO
03/18/16
NO CHANGE
MZHO
Thermo Fisher has room to raise Affymetrix bid, says Mizuho
Mizuho analyst Eric Criscuolo thinks Thermo Fisher (TMO) has room to counter Origin Technologies' offer for Affymetrix (AFFX) and it still be a good acquisition. If Thermo raises its bid, even to something "modestly above" $16.10 per share, the takeover valuation would still be "reasonable," Criscuolo tells investors in a research note after Origin announced a bid of $16.10 per share for Affymetrix. Other companies that could receive buyout attention should Thermo walk away include Fluidigm (FLDM), Luminex (LMNX) and NanoString (NSTG), the analyst contends.
04/01/16
LEER
04/01/16
NO CHANGE
Target $20
LEER
Outperform
Fluidigm remains top micro-cap pick at Leerink
Leerink analyst Dan Leonard says Fluidigm remains top micro-cap pick, following his MEDACorp survey of next-generation sequencing lab directors that offered some "incremental comfort" on the company's key single cell products and supported his long-term thinking. Leonard believes Fluidigm's business can return to double-digit organic growth in 2016 and revenue acceleration could lead to multiple expansion. The analyst reiterates an Outperform rating and $20 price target on the shares.
04/12/16
LEER
04/12/16
NO CHANGE
Target $15
LEER
Outperform
Fluidigm price target lowered to $15 from $20 at Leerink
Leerink analysts led by Dan Leonard lowered Fluidigm's price target to $15 from $20 following the company's disclosure that the new 800 cell chip for medium-sized cells on its C1 instrument is now a Q4 event, and not a Q2 event as previously thought. Leonard said he is increasingly "wary" that the launch of ultra-high throughput, 10,000 cell chip is a 2017 event. The analyst maintains an Outperform rating on Fluidigm shares.
10/13/16
CANT
10/13/16
NO CHANGE
CANT
Fluidigm outlook still positive, says Cantor
After Fludigm reported weaker than expected results, Cantor analyst Bryan Brokmeier is "concerned that the company may be seeing continued weakness in both BioMark and C1 instrument sales," and he thinks that the C1 and Applied businesses may be suffering from low utilization rates. .Brokmeier cut his price target on the stock to $9 from $11, but he continues to believe that the company can obtain a "significant share of the rapidly growing single-cell biology market over the next three to five years." The analyst thinks that the company can turn itself around soon ,and he keeps a Buy rating on the shares.
INSY Insys Therapeutics
$11.87

-0.34 (-2.78%)

04/14/16
04/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) initiated with a Sell at Evercore ISI by analyst Ken Talanian, who found it unclear whether the current management will be able to "facilitate significant change." He adds that the stock's current valuation overestimates the company's ability to reduce cost and return to growth. 2. Insys Therapeutics (INSY) initiated with a Buy at Janney Capital with analyst Ken Trbovich saying the company's pipeline is "too compelling to ignore." He said that the FDA approval and launch of its Syndros product should offset the weakness from Subsys. 3. Simon Property (SPG) initiated with a Buy at Mizuho. 4. AcelRx (ACRX) initiated with a Neutral at Janney Capital. 5. Intuit (INTU) initiated with a Buy at Brean Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/16
JANY
07/05/16
NO CHANGE
Target $22
JANY
Buy
Insys approval of Syndros may trigger short squeeze, says Janney Capital
Janney Capital analyst Ken Trbovich said in a note published on July 1 that the potential approval of Syndros was one of three potential catalysts expected in the next six months that may trigger a short squeeze in shares of Insys Therapeutics. Insys announced this morning that the FDA has approved Syndros for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. In his prior note, Trbovich set a $22 fair value estimate and Buy rating on Insys shares, which are up 20% to $16.18 in pre-market trading.
08/26/16
JANY
08/26/16
NO CHANGE
Target $22
JANY
Buy
Illinois 'highly unlikely' to be able to bar Insys sales, says Janney Capital
Janney Capital analyst Ken Trbovich said he thinks it is "highly unlikely" that Illinois' Attorney General will succeed with her proposal to ban Insys Therapeutics from doing business in the state, pointing to the fact that a similar attempt by Massachusetts in 2014 was struck down by a federal judge. This story, and the trading in its wake yesterday, clearly indicate Insys has headline risks from ongoing state and federal investigations, acknowledged Trbovich, but he thinks the risk will be eliminated by a settlement for an amount the company can manage from its existing cash. The analyst keeps a Buy rating and $22 fair value estimate on Insys shares, which fell about 4.6% yesterday to close at $14.98.
08/04/16
JEFF
08/04/16
NO CHANGE
Target $22
JEFF
Buy
Insys Therapeutics price target raised to $22 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Insys Therapeutics to $22 saying Subsys scripts appear to have stabilized following the company's in-line Q2 results. The most important element of earnings call was the comment that "we're very optimistic that it [settlement with the DOJ] could happen by end of the year," Steinberg tells investors in a research note. The analyst views the Department of Justice investigation as "by far the most important overhang to the story." He keeps a Buy rating on Insys.
ULTA Ulta Beauty
$238.97

2.31 (0.98%)

08/26/16
DBAB
08/26/16
NO CHANGE
Target $280
DBAB
Hold
Ulta Beauty price target increased to $280 from $225 at Deutsche Bank
Deutsche Bank analyst Mike Baker said Ulta Beauty reported a "terrific" quarter by "almost any measure," but noted that expectations for the retailer have become so high that in-line to slightly better result likely aren't a major positive catalyst for the stock at current levels. Baker raised his price target on Ulta shares to $280 from $225 but keeps a Hold rating on the stock.
08/26/16
COWN
08/26/16
NO CHANGE
Target $286
COWN
Outperform
Ulta Beauty weakness a buying opportunity, says Cowen
Cowen analyst Oliver Chen said the Street's high expectations for Ulta Beauty were likely already priced into the shares, so he recommends buying the shares on the post-earnings weakness. The analyst was most encouraged by the high same-store sales and gross margins improvement. Chen reiterates his Outperform rating and raised his price target to $286 from $265 on Ulta Beauty shares.
10/11/16
BARD
10/11/16
NO CHANGE
Target $305
BARD
Outperform
Ulta Beauty risk/reward attractive ahead of investor day, says Baird
Baird analyst Mark Altschwager previewed Ulta Beauty's investor day and said the recent pullback in the shares has lead to an attractive risk/reward for investors. The analyst expects management's tone to be upbeat, for them to update progress on long term goals, and for them to clarify revenue/unit potential, margin drivers, and supply chain initiatives. Altschwager reiterated his Outperform rating and $305 price target on Ulta Beauty shares.
08/24/16
BARD
08/24/16
NO CHANGE
Target $300
BARD
Outperform
Ulta Beauty price target raised to $300 from $280 at Baird
Baird analyst Mark Altschwager raised his price target on Ulta Beauty to $300 from $280 in anticipation of solid Q2 trends, including comps and earnings that he expects to be at least in line with consensus expectations. The analyst believes the Ulta growth story remains underappreciated by the market and that its strong management justifies its premium valuation. Altschwager reiterated his Outperform rating on Ulta Beauty shares.
VAC Marriott Vacations

02/05/16
02/05/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with an Outperform at Telsey Advisory... AbbVie (ABBV) initiated with an Outperform at William Blair... CBS (CBS) initiated with an Outperform at Telsey Advisory... Criteo (CRTO) initiated with an Outperform at Boenning & Scattergood... LHC Group (LHCG) initiated with a Buy at Jefferies... Marriott Vacations (VAC) initiated with an Outperform at Credit Suisse... Prestige Brands (PBH) initiated with an Overweight at Piper Jaffray... Rubicon Project (RUBI) initiated with an Outperform at Boenning & Scattergood... TESARO (TSRO) initiated with a Buy at Lake Street... Time Warner (TWX) initiated with an Outperform at Telsey Advisory... TubeMogul (TUBE) initiated with a Neutral at Boenning & Scattergood... Viacom (VIAB) initiated with an Outperform at Telsey Advisory... Wyndham (WYN) initiated with a Neutral at Credit Suisse.
02/04/16
FBCO
02/04/16
INITIATION
Target $66
FBCO
Outperform
Marriott Vacations initiated with an Outperform at Credit Suisse
Target $66.
01/04/16
01/04/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American States Water (AWR) initiated with an Underweight at Barclays... Atlassian (TEAM) initiated with a Buy at Canaccord... Belmond Ltd (BEL) initiated with an Underperform at Telsey Advisory... Callaway Golf (ELY) initiated with a Buy at Ladenburg... Choice Hotels (CHH) initiated with a Market Perform at Telsey Advisory... FireEye (FEYE) initiated with a Buy at Summit Research... Five9 (FIVN) initiated with an Outperform at Northland... Hilton (HLT) initiated with an Outperform at Telsey Advisory... Hyatt (H) initiated with a Market Perform at Telsey Advisory... InterContinental (IHG) initiated with a Market Perform at Telsey Advisory... MEG Energy (MEGEF) initiated with an Outperform at RBC Capital... MKS Instruments (MKSI) initiated with an Overweight at Pacific Crest... Marriott Vacations (VAC) initiated with a Market Perform at Telsey Advisory... Marriott (MAR) initiated with a Market Perform at Telsey Advisory... Park National (PRK) initiated with a Neutral at Boenning & Scattergood... Planet Fitness (PLNT) initiated with a Buy at Roth Capital... Skechers (SKX) initiated with a Market Perform at Cowen... Skyworks (SWKS) reinstated with an Overweight at Barclays... Veeva (VEEV) initiated with a Buy at Needham... Wyndham (WYN) initiated with an Outperform at Telsey Advisory... XO Group (XOXO) initiated with a Buy at Axiom.
01/04/16
TLSY
01/04/16
INITIATION
Target $64
TLSY
Market Perform
Marriott Vacations initiated with a Market Perform at Telsey Advisory
Target $64.
HDP Hortonworks
$7.46

-1.24 (-14.25%)

10/13/16
GSCO
10/13/16
DOWNGRADE
Target $7
GSCO
Sell
Hortonworks downgraded to Sell from Buy at Goldman
Goldman analyst Jesse Hulsing downgraded Hortonworks two notches to Sell from Buy and lowered its price target to $7 from $13. The analyst his previous thesis of sustained growth from ongong Hadoop adoption and improved efficiency due to higher mix of expansions was wrong. He expects increased competition for new analytics workloads from cloud services vendors will challenge Hortonworks' pure open source business model and is concerned that FY17 Street billings estimates are too high.
09/30/16
COWN
09/30/16
NO CHANGE
COWN
Hortonworks checks 'concerning,' quarter at risk, says Cowen
Cowen analyst J. Derrick Wood said his checks suggest there have been many high-level employee departures at Hortonworks (HDP) and he also thinks that sales productivity is constrained, presenting risk to its quarterly results. Meanwhile, he said that his checks on Teradata (TDC) remain constructive, noting that he is hearing the company is already signing orders for cloud with its core analytical database products now available on AWS. There are "some encouraging data points" for Tableau (DATA), said Wood, who added that he still has more field work to do around its quarter.
08/08/16
RSBL
08/08/16
INITIATION
Target $20
RSBL
Buy
Hortonworks initiated with a Buy at Rosenblatt
Rosenblatt analyst Marshall Senk initiated Hortonworks with a Buy and $20 price target saying the combination of high renewal rates and customer revenue growth will serve to drive the P&L toward profitability over the next few years.
08/05/16
NEED
08/05/16
DOWNGRADE
NEED
Hold
Hortonworks downgraded to Hold at Needham
As previously reported, Needham analyst Richard Kugele downgraded Hortonworks to Hold from Buy following a slight miss in Q2 and lower guidance. The analyst says he is "stepping aside" as the company works through its sales issues.
ESPR Esperion
$12.32

-0.58 (-4.50%)

07/05/16
WBTH
07/05/16
DOWNGRADE
WBTH
Hold
Esperion downgraded to Hold from Buy at WallachBeth (pre-open)
06/29/16
LEHM
06/29/16
DOWNGRADE
LEHM
Equal Weight
Esperion downgraded to Equal Weight from Overweight at Barclays
07/05/16
UBSW
07/05/16
DOWNGRADE
Target $11
UBSW
Neutral
Esperion downgraded to Neutral from Buy at UBS
UBS analyst Jeffrey Hung downgraded Esperion Therapeutics to Neutral citing an uncertain U.S. regulatory pathway after the FDA did not specifically state that LDL-lowering data could be used for accelerated approval. The analyst cut his price target for the shares to $11 from $69.
06/29/16
06/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. HeartWare (HTWR) downgraded to Equal Weight from Overweight at Barclays by analyst Matthew Taylor, saying he does not expect a competing takeover bid to Medtronic's (MDT) offer. The analyst raised his price target for the shares to $58 from $35. Similarly, shares were downgraded to Market Perform from Outperform at Wells Fargo, with analyst Larry Biegelsen saying he sees a low likelihood that a higher bidder will emerge. The analyst believes Medtronic paid a fair valuation for HeartWare. HeartWare was also downgraded to Neutral from Buy at BTIG. 2. Esperion (ESPR) downgraded to Neutral from Overweight at JPMorgan by analyst Jessica Fye, who slashed her price target for shares to $15 from $50. The analyst says last night's regulatory update is a net negative. Disappointingly, the FDA did not sign off on the use of LDL-C lowering as an acceptable regulatory endpoint for approval of bempedoic acid for the treatment of statin-intolerant patients, Fye tells investors in a research note. The analyst still believes bempedoic acid is an effective LDL-C lowering agent, but now sees a drawn out path to approval in the U.S. Esperion was also downgraded to Underperform at Neutral at Credit Suisse by analyst Vamil Divan, who says the update on the development plans for bempedoic acid leaves him increasingly concerned about the products outlook in the U.S. market. The analyst was surprised that the FDA may not be willing to allow LDL-C as a surrogate endpoint for initial approval but believes there will be significant pressure, and limited upside, on shares until that certainty is obtained, and that process may take years to play out. Esperion was also downgraded to Sector Perform from Outperform at RBC Capital. 3. Comerica (CMA) downgraded to Underperform from Neutral at BofA/Merrill, which reduced its price target to $36 from $45. The firm's analyst lowered estimates 8% below consensus for 2016 and 17% below consensus in 2017 due to low rates that will pressure spread revenue growth, slower U.S. economic growth, and continued reserve build. The firm also downgraded Regions Financial (RF), Synovus (SNV), Texas Capital (TCBI) and Franklin Financial Network (FSB) to Neutral from Buy, as well as Zions Bancorp (ZION) to Underperform from Neutral. 4. comScore (SCOR) downgraded to Neutral from Positive at Susquehanna, citing uncertainty surrounding its accounting issues. The firm continues to like the long-term fundamental story, but with an unclear timeline for its resolution, they are moving to the sidelines. Susquehanna lowered its price target to $18 from $30 on comScore shares. 5. Harman (HAR) downgraded to Sector Perform from Outperform at RBC Capital partly based on the low number of new car launches next year, the firm's forecast for reduced production by the company's European customers, and the firm's reduction in its U.S. auto production versus its previous forecast. Additionally, the firm expects GM (GM) to delay a number of its connected car launches that had been slated for fiscal 2017 until fiscal 2018. The firm lowered its price target to $73 from $85. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

VNCE

Vince Holding

$4.55

0.35 (8.33%)

20:25
12/07/16
12/07
20:25
12/07/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

NWBO

Northwest Biotherapeutics

$0.55

0.0227 (4.33%)

20:17
12/07/16
12/07
20:17
12/07/16
20:17
Hot Stocks
Northwest Biotherapeutics to delist from Nasdaq, confirms clinical trial plans »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$111.03

1.08 (0.98%)

, MSFT

Microsoft

$61.37

1.42 (2.37%)

20:07
12/07/16
12/07
20:07
12/07/16
20:07
Periodicals
NHL in negotiations to bring Apple devices to team benches, TSN says »

The NHL has told teams it…

AAPL

Apple

$111.03

1.08 (0.98%)

MSFT

Microsoft

$61.37

1.42 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Mar

ATKR

Atkore

$19.71

-0.11 (-0.55%)

19:59
12/07/16
12/07
19:59
12/07/16
19:59
Syndicate
Atkore 8M share Secondary priced at $19.00 »

Credit Suisse, Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$26.20

-2.23 (-7.84%)

19:58
12/07/16
12/07
19:58
12/07/16
19:58
Syndicate
Blueprint Medicines 5M share Secondary priced at $25.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CFO says early Q4 trends strengthened into December »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CEO highlights Q3 gross margin, reports 11% comp growth in pants »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CVX

Chevron

$114.44

1.68 (1.49%)

19:20
12/07/16
12/07
19:20
12/07/16
19:20
Hot Stocks
Chevron announces $19.8B capital, exploratory budget for 2017 »

Chevron announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

X

U.S. Steel

$37.49

1.54 (4.28%)

18:49
12/07/16
12/07
18:49
12/07/16
18:49
Periodicals
U.S. Steel CEO: Company may bring back 10,000 U.S. jobs, CNBC says »

U.S. Steel could bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda

$15.40

-0.6 (-3.75%)

18:47
12/07/16
12/07
18:47
12/07/16
18:47
Hot Stocks
Vanda settles Fanapt patent litigation with Apotex »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AE

Adams Resources

$42.31

-0.68 (-1.58%)

, SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

18:46
12/07/16
12/07
18:46
12/07/16
18:46
Hot Stocks
Adams Resources appoints Josh Anders as CFO »

Adams Resources &…

AE

Adams Resources

$42.31

-0.68 (-1.58%)

SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EZPW

EZCORP

$11.80

0.05 (0.43%)

18:42
12/07/16
12/07
18:42
12/07/16
18:42
Earnings
EZCORP reports Q4 EPS with items (31c), may not compare to consensus 6c »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RICE

Rice Energy

$24.59

-0.16 (-0.65%)

18:33
12/07/16
12/07
18:33
12/07/16
18:33
Initiation
Rice Energy initiated  »

Rice Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.42

5.7 (0.75%)

18:30
12/07/16
12/07
18:30
12/07/16
18:30
Periodicals
Amazon spokesperson denies 2,000 grocery stores report, CNET says »

Following a report by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$9.26

0.14 (1.54%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Iconix Brand reports employment termination of Chief Strategy Officer Blumberg »

Iconix Brand disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Puma Biotechnology 'pleased' to complete biomarker analysis of neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTK

Flotek

$11.10

-2.01 (-15.33%)

18:17
12/07/16
12/07
18:17
12/07/16
18:17
Hot Stocks
Flotek: Reviewing FourWorld Capital short report, remain confident in product »

Speaking earlier during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
Puma Biotechnology 'pleased' with preliminary neratinib activity »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNM

PNM Resources

$32.05

0.45 (1.42%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
PNM Resources requests an electric rate increase of $99M in New Mexico »

PNM Resources' New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BK

BNY Mellon

$48.55

0.56 (1.17%)

18:03
12/07/16
12/07
18:03
12/07/16
18:03
Periodicals
BNY Mellon outage led to certain Swift payment failures, WSJ reports »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:52
12/07/16
12/07
17:52
12/07/16
17:52
Hot Stocks
Tailored Brands up 22% to $23.20 after Q3 results beat estimates »

The company also raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

, UNH

UnitedHealth

$159.40

2.08 (1.32%)

17:50
12/07/16
12/07
17:50
12/07/16
17:50
Hot Stocks
Flexsteel names Eric Rangen chair of the board »

Flexsteel Industries…

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

UNH

UnitedHealth

$159.40

2.08 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.10

1.53 (3.03%)

, UA

Under Armour

$27.03

1.62 (6.38%)

17:49
12/07/16
12/07
17:49
12/07/16
17:49
Periodicals
Nike losing market share to faster-growing rivals, Barron's reports »

Despite being down nearly…

NKE

Nike

$52.10

1.53 (3.03%)

UA

Under Armour

$27.03

1.62 (6.38%)

ADDYY

adidas

$76.96

1.225 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

T

AT&T

$40.45

1.1 (2.80%)

17:45
12/07/16
12/07
17:45
12/07/16
17:45
Conference/Events
AT&T management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

EFC

Ellington Financial

$16.30

0.2 (1.24%)

17:41
12/07/16
12/07
17:41
12/07/16
17:41
Hot Stocks
Ellington Financial reports estimated book value per share $19.80 as of Nov 30 »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.